The following video is part of our "Motley Fool Conversations" series, in which health-care editor and analyst David Williamson and consumer goods editor and analyst Austin Smith discuss topics across the investing world.
The roller coaster ride for best-in-class multiple sclerosis drug Tysabri looks like it is coming to a satisfying conclusion for investors, and for about half the population struggling with MS. David and Austin discuss how a new test has changed the fortune of this drug, and its makers, in this video.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
